Prurigo nodularis and pembrolizumab: A therapeutic challenge

Eur J Cancer. 2019 Mar:110:8-10. doi: 10.1016/j.ejca.2019.01.012. Epub 2019 Feb 5.
No abstract available

Keywords: Anti PD-1; Lidocaine; Pembrolizumab; Prilocaine; Prurigo nodularis.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antipruritics / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Dermatologic Agents / therapeutic use
  • Drug Eruptions / etiology*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Middle Aged
  • Prurigo / chemically induced*
  • Prurigo / drug therapy
  • Prurigo / radiotherapy
  • Treatment Outcome
  • Ultraviolet Therapy / methods

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Antipruritics
  • Dermatologic Agents
  • pembrolizumab